Clinical trial NCT03562949: A BE Study to Compare Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg and QVAR® 40 mcg, Inhalation Aerosol
Official title: A Randomized, Multiple-Dose, Placebo-Controlled, Multi-Center Study Comparing Beclomethasone Dipropionate Inhalation Aerosol, 40 mcg to QVAR® 40 mcg (Beclomethasone Dipropionate HFA), Inhalation Aerosol in Treatment of Subjects With Asthma
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Asthma
Lead sponsor: Amneal Ireland Limited
Sponsor class: INDUSTRY
First posted: 2018-06-20
Enrollment: 761
Sex: ALL
Minimum age (years): 18
Maximum age (years): 70
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To compare the efficacy and safety profiles of Beclomethasone dipropionate Inhalation Aerosol, 40 mcg (test product) and QVAR 40 mcg (beclomethasone dipropionate HFA), Inhalation Aerosol (reference product) and to demonstrate that the efficacy of the 2 active products is superior to that of placebo in the treatment of subjects with asthma.


Eligibility criteria: Inclusion Criteria:

* Adult male or female subjects of non-childbearing or of childbearing potential committing to consistent and correct use of an acceptable method of birth control.
* Diagnosis of asthma as defined by the National Asthma Education and Prevention Program at least 12 months prior to screening.
* Pre-bronchodilator FEV1 of \>45% and \<85% of predicted value during the screening visit and on the first day of treatment.
* \>15% and \>0.20 L reversibility of FEV1 within 30 minutes following 360 mcg of albuterol inhalation (pMDI).
* Patients should be stable on their chronic asthma treatment regimen for at least four weeks prior to enrollment.
* Currently non-smoking; had not used tobacco products (i.e., cigarettes, cigars, pipe tobacco) within the past year, and having had \<10 pack-years of historical use.
* Ability to replace current short-acting β agonist (SABAs) with salbutamol/albuterol inhaler for use as needed for the duration of the study. Subjects should be able to withhold all inhaled SABAs for at least six hours prior to lung function assessments on study visits.
* Ability to discontinue their asthma medications (inhaled corticosteroids and long-acting β agonists) during the run-in period and for remainder of the study.
* Willingness to give their written informed consent to participate in the study.

Exclusion Criteria:

* Life-threatening asthma, defined as a history of asthma episodes(s) requiring intubation, and/or associated with hypercapnia, respiratory arrest or hypoxic seizures, asthma related syncopal episode(s), or hospitalizations within the past year prior to the screening or during the run-in period.
* Significant respiratory disease other than asthma (COPD, interstitial lung disease, etc.)
* Evidence or history of clinically significant disease or abnormality including congestive heart failure, uncontrolled hypertension, uncontrolled coronary artery disease, myocardial infarction, or cardiac dysrhythmia. In addition, historical or current evidence of significant hematologic, hepatic, neurologic, psychiatric, renal, or other diseases that, in the opinion of the investigator, would put the patient at risk through study participation, or would affect the study analyses if the disease exacerbates during the study.
* Viral or bacterial, upper or lower respiratory tract infection, or sinus, or middle ear infection within four weeks prior to the screening, during the run-in period, or on the day of treatment.
* Hypersensitivity to any sympathomimetic drug (e.g., albuterol) or any inhaled, intranasal, or systemic corticosteroid therapy.
* Patients receiving β2-blockers, anti-arrhythmics, anti-depressants, and monoamine oxidase inhibitors within 4 weeks prior to the screening.
* Patients who required systemic corticosteroids (for any reason) within the past 2 months.

Primary outcomes:
measure: Baseline-adjusted, pre-dose FEV1 on the last day of the 4-week treatment period
timeFrame: 4 weeks
Secondary outcomes:
Other outcomes:
measure: Number and type of adverse events
timeFrame: Minimum of a 2-week run-in period followed by a 4-week treatment period
Locations:
city: Huntington Beach
country: United States
facility: Beach Clinical Research, Inc.
state: California
city: Los Angeles
country: United States
facility: Downtown La Research Center
state: California
city: Doral
country: United States
facility: Moonshine Research Center
state: Florida
city: Miami Lakes
country: United States
facility: San Marcus Research Clinic, Inc.
state: Florida
city: Miami
country: United States
facility: Hope Clinical Trials, Inc.
state: Florida
city: Naples
country: United States
facility: Advanced Research for Health Improvement
state: Florida
city: Orlando
country: United States
facility: Florida Institute for Clinical Research
state: Florida
city: Palmetto Bay
country: United States
facility: Innovation Research Center
state: Florida
city: Winter Park
country: United States
facility: Florida Premier Research Institute
state: Florida
city: Monroe
country: United States
facility: Monroe BioMedical Research
state: North Carolina
city: Boerne
country: United States
facility: TTS Research
state: Texas
city: Splendora
country: United States
facility: PCP for Life/ Mercury Clinical Research
state: Texas
Study officials:
affiliation: Amneal Pharmaceuticals, LLC
name: Irshad Haque
role: STUDY_DIRECTOR
References: